AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34230975 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid alone (neutral comparator)
Number of subjects: 36
Study 34704539 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.2 g.kg‐1 body mass)
Number of subjects: 11
Study 34704539 — intervention group
Group type: COMPARATOR
Intervention: PLA (sodium chloride placebo 0.2 g.kg‐1 BM)
Number of subjects: 11
Study 34704539 — intervention group
Group type: COMPARATOR
Intervention: CON (no supplementation)
Number of subjects: 11
Study 34606495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed Printed Summary
Number of subjects: 384
Study 34606495 — intervention group
Group type: COMPARATOR
Intervention: No Mailed Printed Summary
Number of subjects: 384
Study 34606495 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Webpage
Number of subjects: 384
Study 34606495 — intervention group
Group type: EXPERIMENTAL
Intervention: Email List Invitation
Number of subjects: 384
Study 32193660 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual-directed exercise training (DVD), thrice-weekly sessions of 15 min for 12 weeks
Number of subjects: 24
Study 32193660 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON), continued habitual lifestyle with no physical exercise
Number of subjects: 24
Study 35718621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention H (High): targeted CPB flow 3.0 L/min/m2 and mean arterial pressure (MAP) 80 mmHg
Number of subjects: 20
Study 35718621 — intervention group
Group type: COMPARATOR
Intervention: Intervention N (Normal): targeted CPB flow 2.4 L/min/m2 and MAP 65 mmHg
Number of subjects: 20
Study 34178020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonas program
Number of subjects: 120
Study 34178020 — intervention group
Group type: COMPARATOR
Intervention: Reading group
Number of subjects: 120
Study 34178020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 35543942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needling combined with oral motor therapy
Number of subjects: 60
Study 35543942 — intervention group
Group type: COMPARATOR
Intervention: Oral motor therapy alone
Number of subjects: 60
Study 32060930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet #1 (65% fat, 15% protein, 20% carbohydrate)
Number of subjects: 10
Study 32060930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet #2 (75% fat, 15% protein, 10% carbohydrate)
Number of subjects: 10
Study 32060930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet #3 (80% fat, 15% protein, 5% carbohydrate)
Number of subjects: 10
Study 33711814 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupressure using an electrostimulation device on the Neiguan (P6) acupuncture point, performed three times a week for one month (12 sessions)
Number of subjects: 135
Study 33711814 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupressure using an electrostimulation device on the Neiguan (P6) acupuncture point
Number of subjects: 135
Study 33711814 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (device attached but not operated)
Number of subjects: 135
Study 33283449 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° reverse Trendelenburg position (15-RTP)
Number of subjects: 120
Study 33283449 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position (HP)
Number of subjects: 120
Study 33283449 — intervention group
Group type: COMPARATOR
Intervention: 5° reverse Trendelenburg position (5-RTP)
Number of subjects: 120
Study 33283449 — intervention group
Group type: COMPARATOR
Intervention: 10° reverse Trendelenburg position (10-RTP)
Number of subjects: 120
Study 33283449 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HP, 5-RTP, 10-RTP, 15-RTP)
Number of subjects: 120
Study 35621864 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg subcutaneously within 24 h and 2 weeks after PCI
Number of subjects: 102
Study 35621864 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin (2 mg/day) alone
Number of subjects: 102
Study 35621864 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 102
Study 35621864 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab therapy
Number of subjects: 102
Study 34759036 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 0
Study 34759036 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32228288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulce Digital
Number of subjects: 126
Study 32228288 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 36075591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with governor vessel moxibustion, applied once daily for 3 weeks (21 treatments total).
Number of subjects: 70
Study 36075591 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human tumor necrosis factor receptor-antibody type II fusion protein, 25 mg subcutaneously, injected once on every Monday and Friday for 3 weeks (6 injections total).
Number of subjects: 70
Study 33206228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (KIDIMN)
Number of subjects: 50
Study 33206228 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study 36206135 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention/rehabilitation program with remote support (phone) in group 1
Number of subjects: 135
Study 36206135 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention/rehabilitation program with remote support (email) in group 2
Number of subjects: 135
Study 36206135 — intervention group
Group type: COMPARATOR
Intervention: Standard recommendations at discharge (control group)
Number of subjects: 135
Study 33556040 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 1,000 mg
Number of subjects: 24
Study 33556040 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 100 mg
Number of subjects: 24
Study 33556040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33556040 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (combined 1,000 mg and 100 mg)
Number of subjects: 24
Study 32554980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Led Internet-Based Learning and Self-care Program
Number of subjects: 0
Study 32554980 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36014852 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Coenzyme Q10 supplementation
Number of subjects: 118
Study 36014852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 32747743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular vancomycin powder (1 g) applied before wound closure
Number of subjects: 0
Study 32747743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local vancomycin)
Number of subjects: 0
Study 36259219 — intervention group
Group type: EXPERIMENTAL
Intervention: HumiGard™ surgical humidification system
Number of subjects: 0
Study 36259219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no humidification)
Number of subjects: 0
Study 32437626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PVP-I and 5.0% NaF varnish applied every 3 months for 2 years
Number of subjects: 284
Study 32437626 — intervention group
Group type: COMPARATOR
Intervention: 5.0% NaF varnish applied every 3 months for 2 years (control)
Number of subjects: 284
Study 34397814 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive and systematic family participation psychological nursing
Number of subjects: 78
Study 34397814 — intervention group
Group type: COMPARATOR
Intervention: General routine care
Number of subjects: 78
Study 32217479 — intervention group
Group type: EXPERIMENTAL
Intervention: DMS method integrating 7 CCA-based algorithms (CCA, ITCCA, MsetCCA, L1-MCCA, FBCCA, ECCA, TRCA)
Number of subjects: 35
Study 32217479 — intervention group
Group type: COMPARATOR
Intervention: M1 and M2 methods
Number of subjects: 35
Study 35815777 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP Specialist program implemented by existing nursing home staff after standardized training
Number of subjects: 137
Study 35815777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 137
Study 33764531 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based meditation app
Number of subjects: 18
Study 33764531 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18
Study 34435305 — intervention group
Group type: EXPERIMENTAL
Intervention: myblu™ ENDS (exclusive use for 9 days)
Number of subjects: 72
Study 34435305 — intervention group
Group type: EXPERIMENTAL
Intervention: myblu™ ENDS (exclusive use for 5 additional days)
Number of subjects: 72
Study 34435305 — intervention group
Group type: COMPARATOR
Intervention: Combustible cigarette use (after returning from myblu™ ENDS)
Number of subjects: 72
Study 34435305 — intervention group
Group type: COMPARATOR
Intervention: Dual use of myblu™ ENDS and combustible cigarettes
Number of subjects: 72
Study 34435305 — intervention group
Group type: EXPERIMENTAL
Intervention: myblu™ ENDS (overall conclusion)
Number of subjects: 72
Study 32847423 — intervention group
Group type: EXPERIMENTAL
Intervention: SIBP-01 (6 mg•kg-1 intravenous dose)
Number of subjects: 100
Study 32847423 — intervention group
Group type: COMPARATOR
Intervention: Herceptin® (6 mg•kg-1 intravenous dose)
Number of subjects: 100
Study 32847423 — intervention group
Group type: EXPERIMENTAL
Intervention: SIBP-01
Number of subjects: 100
Study 32847423 — intervention group
Group type: COMPARATOR
Intervention: Herceptin®
Number of subjects: 100
Study 33911059 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive religious coping
Number of subjects: 0
Study 33911059 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative religious coping
Number of subjects: 0
Study 33911059 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse caregivers
Number of subjects: 0
Study 36263703 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis supplementation (510 mg per day)
Number of subjects: 44
Study 32426852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin-augmented labor
Number of subjects: 78931
Study 35045813 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing mint gum
Number of subjects: 93
Study 35045813 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality
Number of subjects: 93
Study 35045813 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 93
Study 36261050 — intervention group
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Number of subjects: 200
Study 36261050 — intervention group
Group type: COMPARATOR
Intervention: Cabazitaxel
Number of subjects: 200
Study 36261050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments combined
Number of subjects: 200
Study 34618684 — intervention group
Group type: EXPERIMENTAL
Intervention: AMY-101 (0.1 mg/site) administered via intragingival injections on days 0, 7, and 14
Number of subjects: 32
Study 34618684 — intervention group
Group type: EXPERIMENTAL
Intervention: AMY-101 (0.1 mg/site) administered via intragingival injections
Number of subjects: 32
Study 34618684 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections administered on days 0, 7, and 14
Number of subjects: 32
Study 32474204 — intervention group
Group type: EXPERIMENTAL
Intervention: System-wide multifaceted quality improvement (QI) strategy including electronic alerts, risk assessments, audits, and training.
Number of subjects: 5760
Study 32474204 — intervention group
Group type: COMPARATOR
Intervention: Recommended prophylaxis alone without QI (Control group).
Number of subjects: 5760
Study 33278081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study 33025010 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index‐2010 (HEI‐2010) score
Number of subjects: 158
Study 34743231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT) for 60 minutes at ≥ 10,000 lux
Number of subjects: 49
Study 34743231 — intervention group
Group type: COMPARATOR
Intervention: Sham-placebo treatment
Number of subjects: 49
Study 34743231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT)
Number of subjects: 49
Study 34127491 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with intravenous fluid coloading and phenylephrine infusion
Number of subjects: 76
Study 36068106 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 0
Study 36068106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33910667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy (≥ 160 g/d)
Number of subjects: 104805
Study 33910667 — intervention group
Group type: COMPARATOR
Intervention: Dairy consumption (overall)
Number of subjects: 104805
Study 33910667 — intervention group
Group type: COMPARATOR
Intervention: Dairy consumption (specific foods)
Number of subjects: 104805
Study 32404723 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care program based on modeling and role-modeling theory (5 sessions of 30-45 minutes and 4 phone counseling sessions over 2 weeks)
Number of subjects: 54
Study 32404723 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 54
Study 36123079 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 54
Study 36123079 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 54
Study 33184089 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided blood product transfusion (TEG-BT)
Number of subjects: 162
Study 33184089 — intervention group
Group type: COMPARATOR
Intervention: Traditional blood product transfusion (T-BT)
Number of subjects: 162
Study 33338737 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) program, 16-week, phone-delivered
Number of subjects: 70
Study 33338737 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched diabetes counseling condition
Number of subjects: 70
Study 33338737 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) program
Number of subjects: 70
Study 35987681 — intervention group
Group type: COMPARATOR
Intervention: IVIG alone (2 gr/kg)
Number of subjects: 91
Study 35987681 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG + methylprednisolone (2 gr/kg + 2 mg/kg/day)
Number of subjects: 91
Study 33482893 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) treatment
Number of subjects: 0
Study 33482893 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate SDB treatment with ASV
Number of subjects: 0
Study 33482893 — intervention group
Group type: COMPARATOR
Intervention: No treatment (ASV− group)
Number of subjects: 0
Study 32197407 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake at lunch (quintile 5 vs quintile 1)
Number of subjects: 5517
Study 32197407 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake at dinner
Number of subjects: 5517
Study 32197407 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake at lunch and dinner
Number of subjects: 5517
Study 32197407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fat intake at lunch
Number of subjects: 5517
Study 32197407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate-high protein-moderate fat lunch and low carbohydrate-high protein dinner
Number of subjects: 5517
Study 35333878 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recruitment method
Number of subjects: 2035
Study 35333878 — intervention group
Group type: COMPARATOR
Intervention: Passive recruitment method
Number of subjects: 2035
Study 35333878 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI at baseline
Number of subjects: 2035
Study 35333878 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at recruitment
Number of subjects: 2035
Study 35333878 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of at least 2 kg in the first year
Number of subjects: 2035
Study 34635547 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA 600 mg
Number of subjects: 6
Study 34635547 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 6
Study 32070401 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev)
Number of subjects: 75
Study 32070401 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg PO daily (Let)
Number of subjects: 75
Study 32070401 — intervention group
Group type: EXPERIMENTAL
Intervention: Let/Bev
Number of subjects: 75
Study 32070401 — intervention group
Group type: COMPARATOR
Intervention: Let
Number of subjects: 75
Study 35863467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 1174
Study 35419799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (5 μg)
Number of subjects: 30
Study 35419799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL normal saline)
Number of subjects: 30
Study 33971938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry powder (active)
Number of subjects: 900
Study 33971938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber bioprocessed oat bran (active)
Number of subjects: 900
Study 33971938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry and oats combined (active)
Number of subjects: 900
Study 33971938 — intervention group
Group type: COMPARATOR
Intervention: Reference beverages containing no active bilberry or active oats (control)
Number of subjects: 900
Study 33971938 — intervention group
Group type: EXPERIMENTAL
Intervention: All active interventions
Number of subjects: 900
Study 33234653 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP touching your face intervention (750-word text and 5 min audio description online)
Number of subjects: 1000
Study 33234653 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1000
Study 33234653 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP touching your face intervention
Number of subjects: 1000
Study 34994830 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-centered multielement fusion teaching mode
Number of subjects: 141
Study 34994830 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 141
Study 33625777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 49
Study 33625777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 33046115 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education sessions with grandmothers' attendance
Number of subjects: 64
Study 33046115 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding education sessions without grandmothers' attendance
Number of subjects: 64
Study 33046115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 34569489 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat (25 mg once daily)
Number of subjects: 162
Study 34569489 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin (30 μg every 2 weeks)
Number of subjects: 162
Study 34569489 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 162
Study 34569489 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin
Number of subjects: 162
Study 32662228 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Casuarina pollen on the day before measurement
Number of subjects: 0
Study 32662228 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cypress pollen 3 days prior to measurement
Number of subjects: 0
Study 32662228 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Pinus pollen 3 days prior to measurement
Number of subjects: 0
Study 32662228 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32662228 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential greenness
Number of subjects: 0
Study 32129202 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise training for 12 weeks
Number of subjects: 104
Study 32129202 — intervention group
Group type: COMPARATOR
Intervention: Routine care for 12 weeks
Number of subjects: 104
Study 36375329 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (viloxazine ER, Qelbree®), flexible-dose (200-600 mg)
Number of subjects: 354
Study 36375329 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected up to Week 2
Number of subjects: 354
Study 36375329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 32886746 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session modified Mindfulness-Based Cognitive Therapy (MBCT) for 10 weeks with telephone follow-up
Number of subjects: 113
Study 32516894 — intervention group
Group type: EXPERIMENTAL
Intervention: RTVFD-assisted ventilation (RAV)
Number of subjects: 26
Study 35060969 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factors (CGFs)
Number of subjects: 20
Study 35060969 — intervention group
Group type: COMPARATOR
Intervention: Demineralized Bovine Bone Matrix (DBBM)
Number of subjects: 20
Study 32882710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted trivalent influenza vaccine (aTIV)
Number of subjects: 50012
Study 32882710 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted trivalent influenza vaccine (TIV)
Number of subjects: 50012
Study 34034337 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 40
Study 34034337 — intervention group
Group type: COMPARATOR
Intervention: No Distraction
Number of subjects: 40
Study 32638970 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise for 12 weeks
Number of subjects: 65
Study 33094931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg TDS for 8 weeks
Number of subjects: 150
Study 33094931 — intervention group
Group type: COMPARATOR
Intervention: Calcium tablets as placebo (control)
Number of subjects: 150
Study 32415945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime combined with gamma globulins
Number of subjects: 120
Study 32415945 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 120